ECP treatment for immunotherapy-related colitis or hepatitis in melanoma
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This study tests a treatment called extracorporeal photopheresis (ECP), which filters your blood and treats it with light, for people with advanced melanoma who have severe colon or liver inflammation caused by immunotherapy. The goal is to reduce that inflammation so you can feel better and possibly continue your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced melanoma (stage 3 or 4) that has spread or cannot be removed with surgery.
- You received immunotherapy for your melanoma, but had to pause or stop it because you developed severe colitis (inflammation of the colon) or hepatitis (inflammation of the liver) of grade 2 or higher.
- Your colitis must have been confirmed by an endoscopy (a camera test inside the colon).
- Your colitis or hepatitis did not get better after using steroids.
- You must be in generally decent health (able to do light activities, like walking or light housework) — an ECOG score of 0, 1, or 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma that has not responded to immune checkpoint inhibitors. TIL therapy uses your own immune cells to fight the cancer. The study aims to see if this can help shrink tumors or slow the disease.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.